Literature DB >> 15975326

Randomized clinical stroke trials in 2004.

Meheroz H Rabadi1, John Blass.   

Abstract

Randomized clinical stroke trials published during 2004 dealt primarily with prevention of strokes by reducing risk factors. The usefulness of innovative versions of widely known treatment modalities was documented. These included angiotensin-converting enzyme inhibitors against hypertension, acarabose against diabetes, and the antiplatelet agent triflusal instead of aspirin. A large British study confirmed the value of treatment with simvastatin. Appropriately powered studies found no benefit for stroke prevention of either vitamin treatment to lower homocysteine or hormonal replacement in post-menopausal women. The circumstances under which antithrombotic, anticoagulant and surgical treatments of acute ischemic stroke are appropriate were further specified.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15975326     DOI: 10.1007/s11883-005-0025-1

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  19 in total

1.  MERCI 1: a phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia.

Authors:  Y Pierre Gobin; Sidney Starkman; Gary R Duckwiler; Thomas Grobelny; Chelsea S Kidwell; Reza Jahan; John Pile-Spellman; Alan Segal; Fernando Vinuela; Jeffrey L Saver
Journal:  Stroke       Date:  2004-10-28       Impact factor: 7.914

2.  Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.

Authors:  Jordi Matías-Guiu; José M Ferro; José Alvarez-Sabín; Ferran Torres; M Dolores Jiménez; Aida Lago; Teresa Melo
Journal:  Stroke       Date:  2003-03-20       Impact factor: 7.914

3.  Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.

Authors:  Markolf Hanefeld; Jean Louis Chiasson; Carsta Koehler; Elena Henkel; Frank Schaper; Theodora Temelkova-Kurktschiev
Journal:  Stroke       Date:  2004-04-08       Impact factor: 7.914

4.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Christoph Diener; Julien Bogousslavsky; Lawrence M Brass; Claudio Cimminiello; Laszlo Csiba; Markku Kaste; Didier Leys; Jordi Matias-Guiu; Hans-Jürgen Rupprecht
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

5.  Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial.

Authors:  A Halliday; A Mansfield; J Marro; C Peto; R Peto; J Potter; D Thomas
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

6.  Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.

Authors:  Steven R Levine; Robin L Brey; Barbara C Tilley; J L P Thompson; Ralph L Sacco; Robert R Sciacca; A Murphy; Yimeng Lu; Teresa M Costigan; Candi Rhine; Bruce Levin; Douglas A Triplett; J P Mohr
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

7.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

8.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleight; Richard Peto
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

9.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

10.  Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study.

Authors:  Marian P LaMonte; Marshall L Nash; David Z Wang; Andrew R Woolfenden; John Schultz; Marcie J Hursting; Philip M Brown
Journal:  Stroke       Date:  2004-05-20       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.